Drugs / ASP4132
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02383368 | Mar 2015 → Apr 2018 | lymphoma, refractory malignant neoplasm | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP4132 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02383368 ↗ |
| Action | Inhibit | “mitochondrial complex 1 inhibitor ASP4132” PMID 33830407 ↗ Apr 2021 |